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 Abstract 
  Background/Aims:   We have previously shown that aquaporin-2 (AQP2) is down-regulated in 
the renal medulla of rats made hypertensive by chronic inhibition of nitric oxide synthase. It has 
been shown that AQP2 expression is regulated by the calcineurin/nuclear factor of activated T 
cells (NFATc). Nitric oxide (NO) regulates the activity of NFATc via c-Jun-N-terminal kinase 2 
(JNK2). Therefore, we hypothesized that increases in NO enhance NFATc-mediated up-regula-
tion of AQP2 promoter activity.   Methods:   AQP2 mRNA and protein expression were detected 
in mouse renal papilla.     AQP2 promoter luciferase reporter- and NFAT luciferase reporter-trans-
fected MDCK cells were used to determine AQP2 promoter activity and NFATc activity, respec-
tively. Cells were incubated with classic activators and inhibitors of NFATc and the NO pathway. 
  Results:  Our results demonstrate that both Ca  2+  and NO have a synergistic effect resulting in an 
increase in AQP2 mRNA and protein in mouse papilla and activation of the AQP2 promoter in 
kidney-derived cells. In addition, NO enhances Ca  2+  -induced NFATc activation. The underlying 
mechanism involves increased NFATc nuclear import and decreased export via protein kinase 
G-mediated inhibition of JNK1/2.   Conclusions:   This is the first study defining novel regulatory 
roles for NO and NFATc in the control of AQP2, which is an important renal protein. 
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 Introduction 
 Water transport through aquaporins (AQPs) is the most important mechanism contrib-
uting to kidney water reabsorption [reviewed in ref.   1  ]. AQP expression correlates with the 
water permeability of each nephron segment: both the proximal tubules and the descending 
thin limb of the loops of Henle have high water permeability due to constitutive expression 
of AQP1. The final checkpoint for renal water reabsorption occurs in the collecting duct, 
primarily due to the regulated insertion of AQP2 in the apical membrane of principal col-
lecting duct cells. Water permeability in this nephron region is tightly regulated by arginine 
vasopressin (AVP), which controls AQP2 plasma membrane trafficking and expression [re-
viewed in ref.   1  ].
  Expression of AQP2 is additionally influenced by urine hypertonicity  [2] . Hypertonicity 
regulates the AQP2 promoter independently of AVP   [3]  . Water reabsorption increases along 
the osmotic gradient together with transcription factor tonicity-responsive enhancer bind-
ing protein (TonEBP) expression, a member of the nuclear factor of activated T-cell (NFAT) 
family of transcription factors. This family consists of 5 members, NFAT 1–5, which share a 
highly conserved DNA-binding domain   [4]  . TonEBP (NFAT5), however, differs from the 
NFATc1–NFATc4 isoforms in two noteworthy ways: (1) it binds DNA as a dimer, whereas 
NFATc binds DNA as a monomer forming cooperative complexes with Fos and Jun (activa-
tor protein 1, AP1), which is activated by protein kinase C (PKC)   [5]  , and (2) it protects cells 
from the deleterious effects of high urea by regulating heat shock protein 70 expression and 
by enhancing AQP2 expression   [6, 7]  . In comparison to the established role of TonEBP in 
renal physiology and NFATc in the immune, nervous, and cardiovascular systems   [8–14]  , 
relatively little is known about the role of NFATc in the kidney.
    Li et al.   [15]   have provided evidence that links Ca  2+   signaling and water reabsorption by 
showing that transcription of AQP2 is enhanced by the calcineurin/NFATc-AP1 pathway. The 
authors showed that while TonEBP and calcineurin/NFATc-AP1 pathways separately induce 
AQP2 transcription, a combination of the two pathways enhances AQP2 expression further. 
  NFATc activation is mediated by a large number of external signals that induce a receptor-
mediated increase in intracellular Ca  2+  , ensuing activation of the protein phosphatase, calci-
neurin, which dephosphorylates NFATc leading to its activation and nuclear import   [8]  . In a 
previous paper, we have demonstrated that in vascular smooth muscle, nuclear export of 
NFATc3 has to be down-regulated in order to observe its nuclear accumulation upon calci-
neurin activation   [11]  . Via activation of soluble guanylyl cyclase (sGC) and subsequently pro-
tein kinase G (PKG), NO is required for inhibiting c-Jun-N-terminal kinase 2 (JNK2, a kinase 
that phosphorylates, and therefore deactivates, NFATc), leading to reduced NFATc3 nuclear 
export, while increased intracellular Ca  2+  augments NFATc3 nuclear translocation  [11] . How-
ever, the mechanisms that control NFATc activation have not been explored in kidney cells.
    We have previously shown that AQP2 is down-regulated in the outer and inner renal 
medulla in rats made hypertensive by inhibiting NO synthase (NOS) with chronic adminis-
tration of   L  -NAME   [16]  . Reduced expression of AQP2 in the inner medulla in this chroni-
cally NOS-inhibited hypertensive model may be a compensatory mechanism to reduce blood 
pressure, or it could be due to reduced availability of NO.
    The above discussion led us to hypothesize that increases in NO enhance NFATc-medi-
ated up-regulation of AQP2 expression and that this is accomplished by an underlying mech-
anism involving NO-mediated reduction in NFATc nuclear export by inhibition of JNK1/2. 
Therefore, reduced NO and NFATc activity could be a compensatory mechanism to alleviate 
volume expansion in some hypertensive states. Since the roles of NO and NFATc in regulat-
ing water balance are highly unexplored, the goal of this study was to define a novel pathway 
that contributes to the regulation of AQP2, which is an important renal protein. 126
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  Materials  and  Methods 
  All protocols involving animals employed in this study were reviewed and approved by 
the Institutional Animal Care and Use Committee of the University of New Mexico Health 
Science Center (Albuquerque, N. Mex., USA) and have been carried out in accordance with 
EC Directive 86/609/EEC for animal experiments.
  A n i m a l s  
  FVBN male mice (25–30 g) were used. All animals were maintained on a 12-hour light-
dark cycle with access to food and water ad libitum. Mice were euthanized with an overdose 
of pentobarbital (200 mg/kg i.p.) and both kidneys were removed. Kidney papilla was dis-
sected out, incubated in Opti-MEM (Invitrogen) at 37    °    C for 24 h in the absence or presence 
of 1     M   ionomycin (Ca  2+   ionophore, Calbiochem), 100 n  M   phorbol 12-myristate 13-acetate 
(PMA, PKC/AP1 activator, Sigma), 100     M   spermine NONOate (NO donor, Calbiochem) or 
1     M   AVP (dAVP, Sigma), or different combinations of the drugs.
  Real-Time  PCR 
 Total RNA was isolated using the RNeasy mini kit (Qiagen). Total RNA was reverse tran-
scribed to cDNA using a high capacity reverse transcription kit (A&B). For real-time detec-
tion of AQP2 transcripts (Mm 00437575_m1) and reference gene (    -actin, Mm 00607939_
s1), TaqMan gene expression assays (A&B) were used. The normalized gene expression meth-
od (2  –   C  T  ) for relative quantification of gene expression was used   [17]  .
  Cell  Culture 
 Madin-Darby canine kidney (MDCK) cells (from ATCC)  [18]  were grown in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin antibiotic mixture at 37    °    C in 5% CO  2   with controlled humidity.
    Cells were treated with ionomycin (1     M  ) and PMA (100 n  M  ; Io+PMA in the presence, 
absence, or different combinations of cyclosporine A (CsA, 1     M  , Calbiochem), NO donor 
(100     M  ), sGC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ, 10     M ,  Cal-
biochem), and PKG inhibitor Rp-8-pCPT-cyclic guanosine monophosphate (cGMP), and 
PKGi (10     M  , Calbiochem). Leptomycin B (40 n  M  , Sigma) was used to inhibit NFATc3 nu-
clear export. For the promoter studies, cells were treated for 24 h. For the import/export 
studies, treatment did not last   1 1  h.
  P l a s m i d s  
  9xNFATc luciferase reporter plasmid was kindly provided by Dr. Molkentin (Depart-
ment of Pediatrics, Children’s Hospital Medical Center, Cincinnati, Ohio, USA). The 
9xNFATc luciferase plasmid has 9 NFATc binding sites upstream of the luciferase gene.
    AQP2 promoter luciferase reporter plasmid was kindly provided by Dr. Chen (Depart-
ment of Internal Medicine/Renal Division, Washington University School of Medicine, St. 
Louis, Mo., USA). The AQP2 promoter reporter construct contains a 600-bp DNA fragment 
from the mouse AQP2 proximal promoter (nucleotides 8923–9522, GenBank AY055468) 
cloned in a luciferase vector (pGL3-basic vector, Promega). Six NFAT binding sites were pre-
viously identified by Li et al.   [15]   in the AQP2 promoter. Therefore, we also tested mutants 
pAQP2-MT3, pAQP2-MT2, and pAQP2-MT1 in which the putative NFATc sites were mu-
tated by PCR-directed mutagenesis   [15]  . These plasmids were also kindly provided by Dr. 
Chen. pGL3-basic empty vector was used as control. TK-renilla reporter plasmid (Promega) 
was used to normalize for differences in transfection efficiencies.127
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    NFATc3-enhanced green fluorescent protein (EGFP) expression vector was created by 
Dr. F. McKeon (Harvard University, Cambridge, Mass., USA) and kindly provided by Dr. 
L.F. Santana (Washington State University, Seattle, Wash., USA).
    Transient Transfections and Luciferase Assay 
  MDCK cells were transfected with the appropriate combination of vectors using Lipo-
fectamine 2000 reagent (Invitrogen) or Nucleofector (Lonza). Luciferase and renilla    activity 
were simultaneously detected using a dual-luciferase reporter assay system (Promega). Re-
nilla     activity was used to normalize luciferase activity. 
  Fluorescence  Microscopy 
  NFATc3-EGFP-transfected MDCK cells were seeded on microscope coverslips and cul-
tured for at least 24 h. At the time of experimentation, a coverslip was mounted on a heating 
plate chamber and maintained in Opti-MEM at    37   °    C during the experiments. 
    Nuclear EGFP fluorescence was monitored using a Nikon Diaphot 300 at a magnifica-
tion of   !  200. Individual MDCK cells were imaged once every minute for 30 min. Images 
were captured using Andor IQ 1.9 software. Nuclear fluorescence (F) was background cor-
rected and expressed as x-fold change from baseline nuclear fluorescence (F/F  0 ;  Metamorph 
Universal Imaging software). 
    AQP2 was detected by immunofluorescence microscopy in sections of mouse kidney 
papilla. After 24 h of incubation with the treatments described in the animals section, the 
papilla was fixed in 4% formaldehyde in PBS, cryoprotected with 30% sucrose in PBS and 
embedded in OCT. Sections were permeabilized, blocked, and stained with rabbit anti-
AQP2 (1/200, Abcam) followed by anti-rabbit Cy5 (Jackson ImmunoResearch Laborato-
ries). Nuclei were stained with SYTOX Green (Invitrogen). Sections were examined using 
a   !  40 objective on an EVOS fluorescence microscope (AMG). The same fluorescence 
threshold was applied to all the images, and average intensity was determined using Meta-
morph software (Universal Imaging). Specificity of immune staining was confirmed by 
the absence of fluorescence in tissues incubated with primary or secondary antibodies 
alone.
    Detection of p-JNK1/2 Levels by Western Blot 
 MDCK cells were lysed using RIPA buffer (Pierce) at 4    °   C and centrifuged at 16,000  g   for 
2 min. Protein concentration was determined in the supernatant using a BCA protein assay 
kit (Pierce). Supernatants (20     g/lane) were resolved by SDS-PAGE and proteins transferred 
to PVDF membranes. The membranes were blocked with blocking buffer from Odyssey (LI-
COR Biosciences). The membranes were incubated with primary antibodies, rabbit anti-p-
JNK1/2 (pT183/pY185; Invitrogen) 1/100 and mouse anti-    -actin (Sigma) 1/5,000, in 0.1% 
Tween PBS-buffered saline solution at 4    °    C overnight, washed, and incubated for 1 h with 
1/10,000 goat anti-rabbit IRdye 800CW and goat anti-mouse IRdye 680 (LI-COR Bioscienc-
es). The membrane was scanned using the Odyssey infrared imaging system (LI-COR Bio-
sciences). The results were expressed as the ratio between p-JNK1/2 over    -actin  fluores-
cence intensity and normalized to control.
  S t a t i s t i c s  
  Results are expressed as the mean   8   SEM of at least 4 experiments. Statistical signifi-
cance was tested at the 95% (p  !   0.05) confidence level using one- or two-way repeated-mea-
sure ANOVA. NFATc3-EGFP nuclear import and export curves were obtained by non-linear 
regression fit to a one-phase association equation and one-phase exponential decay equation, 
respectively. 128
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  R e s u l t s  
  NO Enhances Ca  2+  /PKC-Induced Increase in AQP2 mRNA and Protein in Mouse Renal 
Papilla 
  We have shown that AQP2 is down-regulated in the outer and inner renal medulla in 
rats made hypertensive by chronic inhibition of NOS  [16] . NFATc has been shown to regulate 
AQP2 expression in mpkCCD  c14   cells (immortalized murine principal collecting duct cells) 
  [15]  . Elevations in intracellular Ca  2+   activate NFATc and activation of PKC increases AP1 
activity/NFATc co-factor [reviewed in ref.   8  ]. Therefore, we tested whether the Ca  2+ /PKC/
NFATc/AP1 pathway regulates AQP2 expression in mouse kidney papilla. This region of the 
kidney was used because it is rich in collecting ducts, and AQP2 is primarily expressed at the 
apical membrane of principal collecting duct cells [reviewed in ref.   1  ]. Isolated papilla from 
mouse kidney was cultured for 24 h in the absence or presence of the calcineurin/NFATc 
activator ionomycin and the PKC/AP1 activator PMA, and mRNA and protein levels were 
measured. dAVP was used as positive control. In addition, we tested whether NO can mod-
ulate any effect of Io+PMA.   Figure 1  a shows that indeed Io+PMA significantly up-regulated 
AQP2 mRNA expression. Co-treatment with NO significantly enhanced Io+PMA-induced   
  Fig. 1.  NO enhances Ca  2+ /PKC-induced increases in AQP2 mRNA and protein expression in mouse renal 
papilla. Renal papilla was isolated from mice and treated for 24 h with vehicle, ionomycin (1     M ),  PMA 
(100 n  M ), NO donor (100    M ), or dAVP (1    M , positive control) in different combinations.  a  AQP2 mRNA 
was detected by real-time PCR (TaqMan assay).   b   Effect of Io+PMA and Io+PMA+NO on AQP2 protein 
expression assessed by immunofluorescence.   *  p   !   0.05 vs. control;   *  *  p   !   0.05 vs. Io+PMA. n = 6 for 
mRNA and n = 3 for protein.   c   Representative images of AQP2 immunofluorescence staining of collect-
ing duct cells of the renal papilla. Scale bar = 100    m. 
  c  129
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increases in AQP2 mRNA expression.   Figure 1  b and   1  c show that NO also significantly en-
hanced Io+PMA-induced increases in AQP2 fluorescence staining in collecting duct cells of 
the renal papilla. 
    Regulation of AQP2 Promoter by NO and NFATc in MDCK Cells 
  In order to explore the mechanism of NO-enhanced Io+PMA-induced up-regulation of 
AQP2 expression, we studied the regulation of AQP2 promoter by NFATc and NO in cul-
tured MDCK cells.
    Li et al.   [15]   have shown that activation of NFATc and AP1 increases AQP2 promoter 
activity in mpkCCD  c14   cells. We have obtained similar results in MDCK cells transfected 
with the same AQP2 promoter luciferase reporter. As expected, AQP2 promoter activity in-
creased in cells treated with Io+PMA (  fig. 2  a). This activation was attenuated by the calci-
neurin inhibitor, CsA. In addition, the same treatments were applied to cells transfected with 
an NFATc reporter confirming that they also increase NFATc activity in these cells (  fig. 2  b). 
These treatments had no effect on cells transfected with empty reporter plasmid (data not 
shown).
    Consistent with our hypothesis, an NO donor had a synergic effect with Io+PMA on 
AQP2 promoter activity (  fig. 3  a) suggesting that NO enhances NFATc activity. NO by itself 
  Fig. 2.    a   Calcineurin/NFATc 
regulates AQP2 promoter. Exper-
iments performed in AQP2 pro-
moter luciferase reporter-trans-
fected MDCK cells.   b   Calcineu-
rin/NFATc pathway is transcrip-
tionally active in MDCK cells. 
Experiments performed in NFAT 
luciferase reporter-transfected 
MDCK cells.  a ,  b  Cells were treat-
ed for 24 h with vehicle, ionomy-
cin (1     M  ), PMA (100 n  M )  and 
CsA (1    M ), or their combination. 
  *  p    !   0.05 vs. control (n = 6). 
RLU = Relative luciferase units. 130
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caused a significant, albeit small, increase in AQP2 promoter activity. NO also enhanced 
Io+PMA-induced increases in NFATc activity (  fig. 3  b). Treatment with NO only had no ef-
fect.
    The role of calcineurin in the synergistic effect of NO and NFATc both in AQP2 pro-
moter and NFATc activity was established by inhibiting calcineurin with CsA. CsA attenu-
ated NO-enhanced NFATc-mediated AQP2 promoter activation (  fig. 3  a). CsA reduced lucif-
erase activity almost to the level of NO treatment alone. Furthermore, CsA prevented NO-
enhanced Io+PMA-induced NFATc activation (  fig. 3  b). 
    In order to determine if NO acts via the previously described cGMP/PKG pathway, cells 
were incubated with an sGC inhibitor, ODQ. ODQ significantly reduced both NO-enhanced 
Io+PMA-induced AQP2 promoter and NFATc activity (  fig. 3  ). 
    NFAT Sites within the AQP2 Proximal Promoter Mediate the Regulation of AQP2 
Expression in Response to Calcium and NO 
 To further determine whether the synergistic effect of NO and Ca  2+ /PKC/AP1 signaling 
is dependent on the demonstrated NFAT binding sites   [15]  , MDCK cells were transfected 
with pAQP2-MT1, pAQP2-MT2, and pAQP2-MT3     constructs that have the first, the last 5, 
or all 6 NFAT binding sites mutated within the proximal   AQP2   promoter. As previously 
  Fig. 3.    a   N O  e n h a n c e s  N F A T c /
AP1-mediated AQP2 promoter 
activity. Experiments performed 
in AQP2 promoter luciferase re-
porter-transfected MDCK cells. 
  b   NO enhances NF A T c activity . 
Experiments performed in NFAT 
luciferase reporter-transfected 
MDCK cells.  a ,  b  Cells were treat-
ed for 24 h with vehicle, ionomy-
cin (1     M  ), PMA (100 n  M ),  CsA 
(1    M ), NO donor (100    M ), ODQ 
(10     M  ), or the combination of 
them.   *  p    !   0.05 vs. control.
  **  p   !   0.05 vs. Io+NO+PMA (n = 
6). RLU = Relative luciferase 
units. 131
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shown by Li et al.   [15]  , the induction by Io+PMA was completely lost in pAQP2-MT3 with 
all 6 sites mutated, confirming the importance of these sites in the induction of   AQP2  pro-
moter (  fig. 4  ). No significant difference was detected in AQP2 promoter activity after stimu-
lation with Io+PMA in pAQP2-MT3-expressing cells. The synergistic effect of NO was also 
absent. In addition, the mutation of 5 sites in pAQP2-MT2     reduced the response to both 
Io+PMA and NO+Io+PMA ( fig. 4 ). There was no difference in the response to both Io+PMA 
and NO+Io+PMA between pAQP2 wild type (WT) and pAQP2-MT1, suggesting the first 
NFAT binding site is not enough to regulate AQP2 promoter activity. We did not observe any 
significant difference in baseline (control) luciferase expression between AQP2 WT and 
mutant-expressing cells (pAQP2-WT = 1.80   8   0.11, pAQP2-MT1 = 1.71   8   0.15, pAQP2-
MT2 = 1.40   8   0.09, pAQP2-MT3 = 1.65   8   0.13 relative luciferase units) suggesting NFATc 
binding sites are not required for basal AQP2 promoter activity.
    NO Affects NFATc Nuclear Accumulation 
 In order to further explore how NO modulates NFATc transcriptional activity, the effect 
of NO on NFATc nuclear import/export was determined. 
    To study NFATc nuclear export, the transcription factor must be localized in the nucle-
us at the beginning of the experiment, so NFATc3-EGFP-transfected cells were treated with 
ionomycin for 1 h prior to commencing the experiment. CsA was then added in the presence 
or absence of NO. The translocation was imaged and analyzed, as described in Materials and 
Methods. As expected, NO significantly attenuated NFATc3-EGFP nuclear export, as shown 
in the representative images and kinetic curves (  fig. 5  a and b, respectively). NO significantly 
increased the plateau of NFATc3 nuclear export (  fig. 6  b).
    In order to determine if NO acts via the previously described cGMP/PKG pathway, 
NFATc3-EGFP-transfected cells were treated with CsA and NO and a selective PKG inhibi-
tor (PKGi). Indeed, PKG inhibition prevented NO-induced reduction in NFATc nuclear ex-
  Fig. 4.   S i n g l e  n u c l e o t i d e  m u t a -
tions in 6 NFATc binding sites 
in the AQP2 promoter prevent 
NFATc-mediated AQP2 promot-
er activation and NO effect. 
MDCK cells were transfected 
with WT AQP2 promoter lucif-
erase reporter and mutated con-
structs MT1, MT2 and MT3 as 
depicted in the upper graph. 
Cells were treated for 24 h with 
vehicle, ionomycin (1     M ),  PMA 
(100 n  M  ), and NO donor (100     M )  
in different combinations.   *  p   !  
0.05 vs. control;   *  *  p   !   0.05 vs. 
Io+PMA within group;   *  *  *  p   !  
0.05 vs. Io+PMA WT;   *  *  *  *  p   !  
0.05 vs. Io+PMA+NO WT (n = 
6). RLU = Relative luciferase 
units. 132
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port ( fig. 5 b). PKGi significantly decreased the rate of NFATc3 nuclear export and the plateau 
( fig. 6 b).
    It is known that phosphorylation by several serine/threonine kinases such as GSK3   , 
calmodulin (CaM) kinase II and JNK1/2 regulate NFATc nuclear export [reviewed in ref.  10 ]. 
Therefore, we determined whether inhibition of these kinases would mimic the effect of NO 
on NFATc nuclear export. NFATc3-EGFP-transfected cells were treated with CsA and 
JNK1/2 inhibitor (JNK1/2i, SP600125, Calbiochem), GSK3   peptide inhibitor (Calbiochem), 
or CaM kinase II inhibitor (KN-93, Calbiochem). JNK1/2 inhibition attenuated NFATc3-
EGFP export to the same extent as the NO donor ( fig. 6 a). Also, notice that JNK1/2 inhibition 
increased the plateau of the export to the same level as NO, and that JNK1/2i also decreased 
the rate of export ( fig. 6 b). GSK3 and CaM kinase II inhibitors had no effect (data not shown).
  To study NFATc3 nuclear import, cells were treated with the chromosomal region main-
tenance-1 (CRM1) exportin inhibitor, leptomycin B, which blocks nuclear export of NFATc3 
and limits normal NFATc3 shuttling in and out of the nucleus. NFATc3-EGFP-transfected 
cells were incubated with ionomycin in the presence or absence of an NO donor. NO sig-
nificantly enhanced NFATc3-EGFP nuclear import, as shown in representative images and 
kinetic curves ( fig. 7 a and b, respectively). Similarly to what was observed for NFATc3 nucle-
ar export, PKG inhibition abolished NO-enhanced NFATc3 nuclear import and JNK1/2 in-
  Fig. 5.   NO decreases NFATc3-
EGFP nuclear export. MDCK 
cells transfected with NFATc3-
EGFP plasmid were pretreated 
with ionomycin (1     M  ) for 1 h to 
induce maximum nuclear accu-
mulation of NFATc3, then CsA 
(1     M  ) was added (time 0) to in-
hibit further NFATc3 nuclear 
import; cells were treated with 
vehicle (control), NO donor (100 
    M  ), and PKGi (10     M  ), and im-
aged for 30 min.  a  Representative 
images of control and NO-treat-
ed cells.   b   Kinetic curve of 
NFATc3-GFP nuclear export. 
Fluorescence was expressed as 
F/F  0   (F 0   = fluorescence at base-
line).  *  p  !  0.05 from 28 to 30 min 
between NO and control and 
NO+PKGi (10     M  ). No signifi-
cant difference is noted between 
control and NO+PKGi. Right 
panel shows a blow-up of the ini-
tial rate of export. 133
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  Fig. 6.   J N K 1 / 2  i n h i b i t i o n  r e d u c e s  N F A T c 3 - E G F P  
nuclear export. MDCK cells transfected with 
NFATc3-EGFP plasmid were pretreated with iono-
mycin (1     M  ) for 1 h to induce maximum nuclear 
accumulation of NFATc3, then CsA (1    M ) was add-
ed (time 0) to inhibit further NFATc3 nuclear im-
port; cells were treated with vehicle (control) or with 
JNK1/2i (SP600125, 80 n  M  ), and imaged for 30 min. 
  a   Kinetic curve of NFATc3-GFP nuclear export. 
  b   Kinetic parameters (rate and plateau) of all the 
treatment groups obtained by fitting the data to a 
one-phase exponential decay equation.  *  p  !  0.05 vs. 
control;   *  *  p   !   0.05 vs. NO and JNK1/2i (n = 4–7). 
  Fig. 7.   N O  e n h a n c e s  N F A T c 3 -
EGFP nuclear import. MDCK 
cells transfected with NFATc3-
EGFP plasmid were imaged for 
30 min under various treat-
ments. Leptomycin B (40 n  M ) 
was used to inhibit NFATc3 nu-
clear export.   a   Representative 
images of ionomycin (1     M )  and 
Io+NO donor (100     M )-treated 
cells.  b  Kinetic curve of NFATc3-
EGFP nuclear import.   *  p   !   0.05 
vs. control (leptomycin B alone) 
and Io+NO+PKGi;  *  *  p  !  0.05 vs. 
Io+PMA (n = 6). 134
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hibition mimicked the effect of NO (  fig. 7  b,   8  a). GSK3 and CaM kinase II inhibitors had no 
effect (data not shown).
  NO  and  Ca 2+   Inactivate JNK2 
  To determine whether NO and the increase in intracellular Ca  2+   lead to inactivation of 
JNK1 and/or JNK2, the level of phosphorylation of JNK1 and JNK2, an index of JNK activ-
ity  [11, 19] , was determined by Western blot in MDCK cells treated with ionomycin, NO and 
both combined. Our results demonstrate that only the treatment with both (Io+NO) signif-
icantly decreased phospho-JNK2 levels ( fig. 9 ). In addition, a strong tendency for a reduction 
in phospho-JNK1 levels was observed (  fig. 9  ). 
  Discussion 
  NO is a unique signaling molecule that is implicated in numerous molecular pathways. 
Our study suggests that NO enhances NFATc-mediated AQP2 expression in mouse renal 
papilla and demonstrates that it enhances NF A T c- mediated A Q P2 promoter activity in 
MDCK cells. Our study supports a novel pathway by which NO might contribute to the reg-
ulation of renal water reabsorption. 
    Elevated water reabsorption can lead to plasma volume increase and hypertension. At 
the same time, NO is known to be diuretic and natriuretic via sGC/PKG activation [reviewed 
in ref.   20, 21  ]; therefore, at the level of the collecting ducts (inner medulla), where the fine-
tuning of urine composition occurs, elevation in NO may enhance NFATc activation, in-
  Fig. 8.   JNK1/2 inhibition enhances NFATc3-EGFP 
nuclear import. MDCK cells transfected with 
NFATc3-EGFP plasmid were imaged for 30 min 
under various treatments. Leptomycin B (40 n  M ) 
was used to inhibit NFATc3 nuclear export.   a   Ki-
netic curve of NFATc3-EGFP nuclear import.  *  p  !  
0.05 from 17 min between groups.   b   Kinetic pa-
rameters (rate and plateau) of all the treatment 
groups obtained by fitting the data to a one-phase 
association equation.   *  p    !   0.05 vs. ionomycin; 
  *  *  p   !   0.05 vs. Io+NO and Io+JNK1/2i (n = 6). 135
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creasing AQP2 expression in order to prevent an excessive loss of water. It is also possible that 
in certain hypertensive states where renal NO levels are decreased   [22]  , a reduction in AQP2 
will compensate for the hypertension   [23]  . 
  We have previously shown that hypertension induced by chronic inhibition of NOS leads 
to a down-regulation in outer and inner medulla AQP2 expression   [16]  . Our current results 
suggest that NO enhances NFATc-mediated AQP2 expression in isolated mouse renal pa-
pilla by regulating AQP2 promoter. Therefore, the reduction in AQP2 expression observed 
in the rats chronically treated with the NOS inhibitor   [16]   might not be due to a compensa-
tory response to the elevated arterial pressure, but may be mainly due to the reduced NO 
levels. Consistent with this possibility, AQP2 expression is blunted in mice lacking all NOS 
isoforms   [24]  , strongly supporting a role for NO in regulating AQP2 expression in the renal 
medulla. Our results also confirm previous findings from Li et al.   [15]   showing that AQP2 
promoter is regulated by the NFATc-AP1 pathway in collecting duct cells. 
    NO by itself caused a significant, albeit small, increase in AQP2 promoter activity but 
had no effect on NFATc activity or NFATc3 nuclear import. Similarly, PKC/AP1 activation 
with PMA increased AQP2 promoter activity but had no effect on NFATc activity (data not 
shown). These results suggest that NO might also lead to an increase in AP1 activity, which 
is consistent with previously reported findings in a variety of cell types   [25–27]  . NFATc ac-
tivation requires Ca  2+  -dependent calcineurin-mediated dephosphorylation, explaining the 
lack of effect of NO by itself on NFATc activity and NFATc3 nuclear import. 
  Fig. 9.  NO and Ca  2+  inactivate JNK2.  a  Representa-
tive Western blot of p-JNK1, p-JNK2, and    -actin 
in MDCK cells treated for 30 min with vehicle (V), 
ionomycin (1     M  ) and NO donor (100     M ). 
  b  Summary of the results.  *  p  !  0.05 vs. control and 
ionomycin (n = 6). 
  a  136
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    In general, NO signaling involves stimulation of sGC to catalyze the conversion of gua-
nosine triphosphate to cGMP, which in turn activates PKG. However, direct effects of NO 
have also been described [reviewed in ref.   28  ]. Our data suggest that NO-enhanced Ca  2+ -
induced NFATc activation is mediated by cGMP. This is supported by the fact that sGC in-
hibition prevented NO-enhanced Ca  2+  -induced NFATc reporter activity.
    The effect of CsA on the ionomycin- or Io+PMA-induced activity of the NFATc pro-
moter is higher than on the AQP2 promoter. Therefore, we cannot discard the partici-
pation of other transcription factors involved in the regulation of the AQP2 promoter 
activity. 
  The primary mechanism for NFATc regulation is through control of its cellular localiza-
tion. Calcineurin, upon activation by Ca  2+  and CaM binding, dephosphorylates NFATc, con-
sequently exposing nuclear localization signals allowing for NFATc nuclear translocation. 
NFATc nuclear accumulation is also controlled by a series of Ser/Thr kinases such as GSK3  , 
CaM kinase II, and JNK1/2 [reviewed in ref.   8, 10  ]. Under non-stimulated conditions, these 
kinases keep NFATc in a highly phosphorylated state in the cytosol. After stimulation and 
once the Ca  2+   signal ends, they re-phosphorylate NFATc, inducing its nuclear export by the 
CRM1 exportin [reviewed in ref.   8, 10  ].
    The enhanced NFATc activity induced by NO could be due to elevated NFATc nuclear 
import, decreased nuclear export, or both. We found that NO affects both NFATc nuclear 
import and export. These effects were mediated by PKG, further demonstrating that NO-
enhanced Ca  2+  -induced NFATc activation is mediated by sGC/cGMP/PKG, and not by a di-
rect effect of NO. 
    It has been shown that NO can nitrosylate and inhibit CRM1, the exportin that trans-
ports NFATc out of the nucleus   [29]  . It is unlikely that NO is decreasing NFATc nuclear ex-
port by nitrosylation of CRM1 because the decreased export was prevented by PKG inhibi-
tion. Also, it is unlikely that this mechanism is mediating NO-enhanced Ca  2+ -induced 
NFATc nuclear import because these experiments were conducted in the presence of the 
CRM1 exportin inhibitor, leptomycin B. 
    NO can also inhibit CaM kinase II by nitrosylation, and CaM kinase II has been shown 
to negatively regulate NFATc in cardiac myocytes  [30, 31] . However, neither GSK3   nor CaM 
kinase inhibitors modified NO-enhanced NFATc nuclear import or NO-decreased NFATc 
nuclear export. 
    JNK1 has been shown to target NFATc, phosphorylating sites required for NFATc inter-
action with calcineurin, resulting in a disruption of calcineurin binding and inhibition of 
NFATc nuclear import   [32]  . JNK2 also targets NFATc in T cells promoting NFATc export 
  [32]  . In addition, we have previously demonstrated that via PKG NO inhibits JNK2, increas-
ing Ca  2+ -induced NFATc3 nuclear accumulation in vascular smooth muscle  [11, 19] . Consis-
tently, we found that an inhibitor of JNK1/2 mimicked the effect of NO on NFATc nuclear 
export and import, suggesting that NO inhibits JNK1/2. These observations are supported 
by the results of Western blot showing significantly decreased p-JNK2 levels and a strong 
tendency to decreased p-JNK1 in cells treated with ionomycin and the NO donor. It has been 
demonstrated that a reduction in JNK phosphorylation correlates with a reduction in kinase 
activity   [11, 19]  . These results indicate that the already established role of JNK2 and JNK1 in 
the regulation of NFATc nuclear export and import in T cells and vascular smooth muscle 
cells, respectively, can be extended to kidney epithelial cells. 
    The signaling between PKG and the inhibition of JNK1/2 is unknown. PKG has been 
reported to activate mitogen-activated protein kinase (MAPK) phosphatase, which suppress-
es the activity of the MAPK cascade   [33, 34]  . Because JNK1/2 is a downstream target of the 
MAPK cascade, it is possible that PKG inactivates JNK1/2 through the activation of MAPK 
phosphatase.137
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    In conclusion, this study supports a novel mechanism by which NO could control renal 
water reabsorption by regulating AQP2 expression via NFATc. In addition, we demonstrate 
that NO enhances NFATc nuclear import and decreases export via PKG. Then, PKG inhibits 
JNK1/2 thereby reducing NFATc phosphorylation, and enhancing NFATc nuclear accumula-
tion and transcriptional activity.
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